Welch J E, Farrar G E, Dunn A J, Saphier D
Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport, LA 71130-3932.
Neuroendocrinology. 1993;57(2):272-81. doi: 10.1159/000126369.
Serotonin (5-HT) is generally considered to serve a facilitatory role in the regulation of adrenocortical secretion. Numerous studies have shown that administration of 5-HT1A receptor agonists increases plasma corticosterone (CS) concentrations in rats; however, the mechanism has not been established. Rats were prepared with a cannula implanted above the lateral cerebral ventricle, or bilateral cannulae above the hypothalamic paraventricular nuclei (PVN), the site of the perikarya of corticotropin-releasing factor (CRF)-secreting neurons regulating adrenocortical secretion. In sodium pentobarbital-anesthetized rats, intracerebroventricular and intra-PVN administration of 5-HT resulted in a multi-component dose-response curve in plasma CS, whereas administration of 5-HT in conscious animals resulted in low-dose inhibition and higher dose elevation of plasma CS levels. Under pentobarbital anesthesia, central administration of the selective 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and ipsapirone decreased plasma CS levels, relative to saline-treated control rats, at all doses tested (0.001-20 nmol). In conscious rats, administration of 8-OH-DPAT decreased adrenocortical secretion at lower doses and significantly increased plasma CS concentrations at higher doses. Ipsapirone produced similar but less pronounced effects. In contrast, intraperitoneal injection of 8-OH-DPAT (2 mumol/kg) increased plasma CS concentrations, but this was not prevented by prior intracerebroventricular administration of the 5-HT1A antagonist, NAN-190 (5 nmol). Pentobarbital anesthesia completely blocked the plasma CS response to peripheral administration of 8-OH-DPAT. In view of the adrenocortical activating effects of hypotensive stimuli, we speculate that the well-documented hemodynamic changes following 5-HT1A receptor stimulation may be responsible for the adrenocortical responses observed. Our data demonstrate that low doses of 5-HT1A agonists delivered directly into the CNS decrease adrenocortical secretion. Since intra-PVN injections of 8-OH-DPAT to pentobarbital-anesthetized rats also decreased hypothalamo-pituitary-adrenocortical activity, it appears that a component of the inhibitory effect of 5-HT1A receptor activation is mediated by a direct effect at the level of the PVN, and presumably involves CRF-secreting neurons.
血清素(5-羟色胺,5-HT)通常被认为在肾上腺皮质分泌调节中起促进作用。大量研究表明,给予5-HT1A受体激动剂可提高大鼠血浆皮质酮(CS)浓度;然而,其机制尚未明确。给大鼠在侧脑室上方植入插管,或在下丘脑室旁核(PVN)上方植入双侧插管,PVN是调节肾上腺皮质分泌的促肾上腺皮质激素释放因子(CRF)分泌神经元胞体所在部位。在戊巴比妥钠麻醉的大鼠中,脑室内和PVN内给予5-HT可使血浆CS呈现多成分剂量反应曲线,而在清醒动物中给予5-HT则导致血浆CS水平低剂量抑制和高剂量升高。在戊巴比妥钠麻醉下,相对于生理盐水处理的对照大鼠,在所有测试剂量(0.001 - 20 nmol)下,选择性5-HT1A激动剂8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)和 ipsapirone的中枢给药均降低了血浆CS水平。在清醒大鼠中,给予8-OH-DPAT在较低剂量时降低肾上腺皮质分泌,在较高剂量时显著提高血浆CS浓度。Ipsapirone产生了类似但不太明显的效果。相比之下,腹腔注射8-OH-DPAT(2 μmol/kg)可提高血浆CS浓度,但预先脑室内给予5-HT1A拮抗剂NAN-190(5 nmol)并不能阻止这种情况。戊巴比妥钠麻醉完全阻断了血浆CS对外周给予8-OH-DPAT的反应。鉴于降压刺激具有肾上腺皮质激活作用,我们推测5-HT1A受体刺激后有充分记录的血流动力学变化可能是观察到的肾上腺皮质反应的原因。我们的数据表明,直接注入中枢神经系统的低剂量5-HT1A激动剂可降低肾上腺皮质分泌。由于向戊巴比妥钠麻醉的大鼠PVN内注射8-OH-DPAT也降低了下丘脑 - 垂体 - 肾上腺皮质活性,似乎5-HT1A受体激活的抑制作用的一部分是由PVN水平的直接作用介导的,大概涉及CRF分泌神经元。